Project Grant R21AI174937
Award Date
8/1/24
Completion Date
6/30/26
Dollars Obligated
$517K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. (UYLKBRENAPG5)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Westlake, MD 20817, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) in the amount of $214,613 to the Veterans Medical Research Foundation of San Diego. The project aims to identify the missing protein or pathway that accounts for the ability of the HIV-1 Nef protein to enhance viral replication and infectivity in a CD4- and Serinc-independent manner. The research will utilize proximity proteomics to search for novel...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,283 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, effective August 16, 2024 through July 31, 2029, will support research to investigate the effects of targeting immune activation and intestinal barrier on comorbidities in people living with HIV. The research aims to advance...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $2,688,880 Project Grant to Emory University to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key products and services to be delivered under this grant include: Comprehensive testing of the effects of IL-15/IL-15RA therapy combined with TGF-beta blockade on different T and NK cell...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a $673,158 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a proteomics atlas of HIV/HBV co-infections for advancing HBV cure strategies. The project aims to use robust co-culture systems, CRISPR screens, and multi-omics approaches in primary human hepatocytes and CD4+ T cells to discover and validate host factors and antivirals against HIV/HBV...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $490,788 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant, titled "Quantifying Genomic and Pharmacometabolomic Differences in Antiretroviral Exposure in MACS/WIHS Combined Cohort Study", aims to identify genetic and metabolic factors that influence the plasma concentrations and associated...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $820,845 to New York University School of Medicine to conduct research aimed at improving HIV outcomes across diverse settings and subgroups in the U.S. HIV epidemic. The research will use mathematical modeling to simulate alternative ways to distribute resources across interventions, settings, and target...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,668,032 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Pittsburgh to conduct research on understanding the mechanisms involved in HIV-1 latency in the central nervous system (CNS). The research aims to identify key factors, pathways, and regulators that control the establishment, maintenance, and reactivation of latent HIV-1 virus in brain myeloid cell...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...